Clinical Trials
176 trialsPhase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
Massachusetts General Hospital
Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Northwestern University
FIERCE
University of Oklahoma
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
Washington University School of Medicine
FID-007 in Treating Participants With Advanced Solid Tumors
University of Southern California
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Dana-Farber Cancer Institute
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
M.D. Anderson Cancer Center
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PAL-ANGI2
Centre Oscar Lambret
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
M.D. Anderson Cancer Center
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
M.D. Anderson Cancer Center
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
University of Alabama at Birmingham
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
University of Colorado, Denver
Testing the Addition of the Anti-cancer Viral Therapy Telomelysinâ„¢ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
M.D. Anderson Cancer Center
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer
Abramson Cancer Center at Penn Medicine
NOVOCURE
University of Utah
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Washington University School of Medicine
GyneRep
University Health Network, Toronto
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
City of Hope Medical Center
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Dana-Farber Cancer Institute
FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer
University of Southern California
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
University of Pennsylvania
'ADVANCE' (A Pilot Trial)
Dana-Farber Cancer Institute
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
University of California, San Diego
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Washington University School of Medicine
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
University of Kentucky
KETO-CARE
Ohio State University Comprehensive Cancer Center
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
University of Chicago
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Peking University Cancer Hospital & Institute
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center